-
Views
-
Cite
Cite
Ryunosuke Nakagawa, Kouji Izumi, Ren Toriumi, Shuhei Aoyama, Taiki Kamijima, Hiroshi Kano, Tomoyuki Makino, Renato Naito, Hiroaki Iwamoto, Hiroshi Yaegashi, Shohei Kawaguchi, Kazuyoshi Shigehara, Takahiro Nohara, Atsushi Mizokami, Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma, Japanese Journal of Clinical Oncology, Volume 54, Issue 12, December 2024, Pages 1329–1335, https://doi.org/10.1093/jjco/hyae101
- Share Icon Share
Abstract
Enfortumab vedotin (EV) is an established pharmacotherapy for metastatic urothelial carcinoma (mUC); however, its adverse events (AEs) cannot be overlooked. The study investigated the efficacy and safety of biweekly EV administration.
Patients with mUC who received EV at our institution were included in the study. Eligible patients were classified into two groups as follows: those who received EV on a standard schedule (standard group) and those who received EV on a biweekly schedule (biweekly group); the treatment outcomes and AEs between the two groups were compared.
Nine and 19 patients were in the standard group and biweekly groups, respectively. The progression-free survival, overall survival, and overall response rate were not significantly different between the two groups. AEs following EV administration, such as decreased appetite (P < .01), pruritus (P < .01), rash maculopapular (P < .01), anemia (P = .04), and liver dysfunction (P = .04), were significantly more frequent in the standard group. Grade 3 or higher AEs, such as pruritus (P = .03) and rash maculopapular (P < .01), were significantly more frequent in the standard group. Furthermore, significantly more patients in the standard group had to be given a reduced dose due to adverse events (P = .02).
Biweekly administration of EV may be safer without compromising therapeutic efficacy than the standard schedule.